Quantbot Technologies’s Aclaris Therapeutics ACRS Stock Holding History

Quantbot Technologies’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20K	Buy	+3,787	New	+$16.9K	﹤0.01%	1782
2023 Q2	–	Sell	-8,700	Closed	-$70.4K	–	1526
2023 Q1	$70.4K	Buy	+8,700	New	+$110K	0.01%	1182
2021 Q4	–	Sell	-765	Closed	-$13K	–	1445
2021 Q3	$13K	Buy	+765	New	+$12.3K	﹤0.01%	1319
2021 Q1	–	Sell	-200	Closed	-$1K	–	1361
2020 Q4	$1K	Buy	+200	New	+$844	﹤0.01%	1211
2018 Q1	–	Sell	-7,204	Closed	-$177K	–	1181
2017 Q4	$177K	Buy	7,204 +3,350	+87%	+$81.6K	0.02%	726
2017 Q3	$99K	Buy	+3,854	New	+$103K	0.01%	842

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Quantbot Technologies's ACRS Position: Q2 2026 in Review

Quantbot Technologies opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 3,787 shares worth $20K. The stake represents ﹤0.01% of the portfolio and ranks #1782 among its holdings. This is a return to the name: Quantbot Technologies previously reported a position in ACRS as recently as Q1 2023.

Quantbot Technologies first reported a position in ACRS in Q3 2017 and has held it in 6 quarters since. The position peaked at $177K in Q4 2017. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Quantbot Technologies held 3,787 shares of Aclaris Therapeutics worth $20K as of Q2 2026.
Aclaris Therapeutics was a new Quantbot Technologies position in Q2 2026.
Aclaris Therapeutics made up ﹤0.01% of Quantbot Technologies's portfolio in Q2 2026, its #1782 holding.
Quantbot Technologies first reported a position in Aclaris Therapeutics in Q3 2017 and has held it in 6 quarters since.
Quantbot Technologies's Aclaris Therapeutics position peaked at $177K in Q4 2017.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Quantbot Technologies's 13F filing for Q2 2026, filed 12 Aug 2026.